This site is intended for health professionals only
Sumatriptan has been used in the management of migraine for over 30 years. The introduction of the 3mg formulation of self-injectable sumatriptan provides another alternative for patients suffering from severe migraine with nausea and vomiting. There are now multiple formulations and doses available, providing physicians and patients more possibilities to find the best solution for managing their pain. These resources were developed to help you understand the differences between the available options and highlight where the 3mg dose fits into the migraine treatment landscape.
3mg subcutaneous sumatriptan is indicated for the acute relief of migraine attacks, with or without aura.
Prescribing information for subcutaneous sumatriptan 3mg and 6mg can be found here.
Tablets, nasal spray, or autoinjector? The number of options for the treatment of severe migraine is expanding, but what are the differences between the different formulations and doses? This handy infographic compares some of the basics of the three formulation types and highlights how the new 3mg option fits into the mix.
Sumatriptan has been used in the management of migraine for over 30 years, but many are not always familiar with the various formulation and dosing options. In this video, learn how self-injectable sumatriptan compares to other formulations and how the introduction of the 3mg dose could help patients suffering from migraine with nausea and vomiting.
Patients can be a bit hesitant when it comes to self-administering an injection. The sumatriptan autoinjector uses a simple click-to-start system to make self-injection easier. This video provides a step-by-step overview of the process.
The introduction of the 3mg dose of injectable formulation of sumatriptan has expanded the options for the management of migraines. Check out the article featured in the May 2021 of Pulse covering the various formulations and introducing the 3mg option.
Subcutaneous sumatriptan is considered the gold standard in treatment of migraine but many patients can be hesitant in using self-injectable medication. In this video, find answers to some of the most pressing questions surrounding self-injectable sumatriptan and the two dose options now available.
Adverse events should be reported. Reporting forms and information can be found at: https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to Ranbaxy UK. Tel: 02088485052.
